Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel targeted oncology treatments for various types of cancer. The enterprise utilizes its proprietary chemistry and biology platforms to advance pipeline candidates—such as azenosertib, an oral WEE1 inhibitor—designed to target specific cellular vulnerabilities in tumors, aiming to improve therapeutic outcomes for cancer patients.